JP5396474B2 - 副腎皮質刺激ホルモン放出因子受容体活性のピラジノンモジュレーター - Google Patents

副腎皮質刺激ホルモン放出因子受容体活性のピラジノンモジュレーター Download PDF

Info

Publication number
JP5396474B2
JP5396474B2 JP2011521135A JP2011521135A JP5396474B2 JP 5396474 B2 JP5396474 B2 JP 5396474B2 JP 2011521135 A JP2011521135 A JP 2011521135A JP 2011521135 A JP2011521135 A JP 2011521135A JP 5396474 B2 JP5396474 B2 JP 5396474B2
Authority
JP
Japan
Prior art keywords
crf
cyclopropyl
mmol
methoxyethyl
calculated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2011521135A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011529886A5 (https=
JP2011529886A (ja
Inventor
リチャード・エイ・ハーツ
ビジャイ・ティ・アフジャ
ビベカナンダ・エム・ブルドゥラ
ジョアン・ジェイ・ブロンソン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2011529886A publication Critical patent/JP2011529886A/ja
Publication of JP2011529886A5 publication Critical patent/JP2011529886A5/ja
Application granted granted Critical
Publication of JP5396474B2 publication Critical patent/JP5396474B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2011521135A 2008-07-31 2009-04-27 副腎皮質刺激ホルモン放出因子受容体活性のピラジノンモジュレーター Expired - Fee Related JP5396474B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8523008P 2008-07-31 2008-07-31
US61/085,230 2008-07-31
PCT/US2009/041793 WO2010014280A1 (en) 2008-07-31 2009-04-27 Pyrazinone modulator of corticotropin-releasing factor receptor activity

Publications (3)

Publication Number Publication Date
JP2011529886A JP2011529886A (ja) 2011-12-15
JP2011529886A5 JP2011529886A5 (https=) 2012-05-24
JP5396474B2 true JP5396474B2 (ja) 2014-01-22

Family

ID=40651774

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011521135A Expired - Fee Related JP5396474B2 (ja) 2008-07-31 2009-04-27 副腎皮質刺激ホルモン放出因子受容体活性のピラジノンモジュレーター

Country Status (10)

Country Link
US (2) US7932256B2 (https=)
EP (1) EP2303867B1 (https=)
JP (1) JP5396474B2 (https=)
KR (1) KR20110040870A (https=)
CN (1) CN102171205B (https=)
AR (1) AR072639A1 (https=)
AU (1) AU2009277057A1 (https=)
MX (1) MX2011000754A (https=)
TW (1) TW201008926A (https=)
WO (1) WO2010014280A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
US10077443B2 (en) 2012-11-15 2018-09-18 Roche Innovation Center Copenhagen A/S Oligonucleotide conjugates
CN104955952A (zh) 2013-01-30 2015-09-30 弗·哈夫曼-拉罗切有限公司 Lna寡核苷酸碳水化合物缀合物
WO2015112642A1 (en) 2014-01-21 2015-07-30 Neurocrine Biosciences, Inc. Crf1 receptor antagonists for the treatment of congenital adrenal hyperplasia
CA3121920A1 (en) 2018-12-07 2020-06-11 Neurocrine Biosciences, Inc. Crf1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia
JP7623365B2 (ja) 2019-09-27 2025-01-28 ニューロクライン バイオサイエンシーズ，インコーポレイテッド Ｃｒｆ受容体アンタゴニストおよび使用方法
IT201900021216A1 (it) 2019-11-14 2021-05-14 Isagro Spa Processo per la preparazione di derivati piridinici e corrispondenti piridil-formammidine
CN112552184B (zh) * 2020-12-18 2022-05-10 诚达药业股份有限公司 一种含环丙基手性胺盐酸盐的合成方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6159980A (en) * 1996-09-16 2000-12-12 Dupont Pharmaceuticals Company Pyrazinones and triazinones and their derivatives thereof
CN1231473C (zh) * 2000-02-16 2005-12-14 神经能质公司 取代的芳基吡嗪
RU2003136151A (ru) * 2001-06-12 2005-05-20 Ньюроджин Корпорейшн (US) 2, 5-диарилпиразины, 2, 5-диарилпиридины и 2, 5-диарилпиримидины в качестве модуляторов рецептора кортикотропин-рилизинг-фактора 1 (крф1)
WO2004046136A1 (en) 2002-11-21 2004-06-03 Pharmacia & Upjohn Company Llc Pyrazine compounds as crf modulators

Also Published As

Publication number Publication date
US7932256B2 (en) 2011-04-26
CN102171205A (zh) 2011-08-31
CN102171205B (zh) 2013-08-07
US20110166160A1 (en) 2011-07-07
AR072639A1 (es) 2010-09-08
TW201008926A (en) 2010-03-01
KR20110040870A (ko) 2011-04-20
AU2009277057A1 (en) 2010-02-04
MX2011000754A (es) 2011-02-24
EP2303867B1 (en) 2014-12-17
WO2010014280A1 (en) 2010-02-04
EP2303867A1 (en) 2011-04-06
US20100029684A1 (en) 2010-02-04
US8372847B2 (en) 2013-02-12
JP2011529886A (ja) 2011-12-15

Similar Documents

Publication Publication Date Title
JP5396474B2 (ja) 副腎皮質刺激ホルモン放出因子受容体活性のピラジノンモジュレーター
KR20030036678A (ko) Ｇａｂａａ 수용체의 리간드로서의 헤테로사이클릭 화합물
CN101918408A (zh) 作为磷酸二酯酶10的抑制剂的芳基和杂芳基稠合的咪唑并[1,5-a]吡嗪
JP2009502959A (ja) セロトニン受容体アゴニストおよびアンタゴニストとしての置換テトラヒドロ−１ｈ−ピリド［４，３，ｂ］インドール
TW200528455A (en) Azabicyclic heterocycles as cannabinoid receptor modulators
CN110997652B (zh) 哌啶酮甲酰基肽2受体激动剂
JP2017523202A (ja) ６，７−ジヒドロピラゾロ［１，５−ａ］ピラジン−４（５Ｈ）−オン化合物およびＭＧＬＵＲ２受容体の負のアロステリック調節因子としてのそれらの使用
WO2003022820A1 (en) Heteroaromatic substituted cyclopropane as corticotropin releasing hormone
CN102123998A (zh) 作为nk3拮抗剂的异喹啉酮衍生物
JP2011513326A (ja) 疼痛症候群および他の障害の治療法
US20040242587A1 (en) Pyrrolo[1,2-b]pyridazine compounds
US7034023B2 (en) Pyrrolo[1,2-B]pyridazine compounds and their uses
SK113399A3 (en) Quinoxalinediones
TW201609718A (zh) 唑啶以及噁嗪烷衍生物
US7056920B2 (en) Pyrrolo[1,2-B]pyridazine compounds and their uses
WO2004035586A1 (en) Pyrrolo[1,2-b]pyridazine compounds and their uses
US20070224636A1 (en) Pyrrolo[1,2b]pyridazine compounds and their uses
US20060166998A1 (en) Pyrrolo[1,2-B]pyridazine compounds and their uses
WO2004092176A1 (en) Pyrrolo[1,2-b]pyridazine compounds and their uses

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120330

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120330

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20131008

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20131021

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees